NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008

RecruitingNA

Sponsor: Fred Hutchinson Cancer Center

Conditions: Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm

Interventions: Dental Cleaning, Dental Plaque sampling

Countries: United States

This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Age ≥ 18 years old
* T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
* One of the following HCT donor types:

  * 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
  * Cord blood
* Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
* Ability to understand and sign a written informed consent document (or legal representative)

Exclusion Criteria:

* Edentulous state
* Bone marrow as graft source
* Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
* Use of anti-thymocyte globulin (ATG) in conditioning
Locations (1)
  • Seattle, Washington, United States